Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab with or without methotrexate for psoriasis
ChiCTR2400085840Phase 4Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of ixekizumab in psoriasis (2 arms), sponsored by Huashan Hospital. Primary endpoint: Clinical efficacy (PASI75/90/100 responses) at week 12. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
ixekizumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on ChiCTR2400085840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085840.